Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
India may issue a warning over cough syrup exported by Marion Biotech linked to a death in Uzbekistan.
Read Full NewsPeople with lower limb motor disability need tailored equipment, training, and medical oversight to boost performance while preventing upper limb overload and skin problems.
Nearly half of maternal deaths from venous thromboembolism in France over 12 years were preventable.
Nearly half of new colorectal cancer cases now occur in people younger than age 65 years, highlighting the need for earlier screening and better symptom awareness.
Tight glycemic targets in gestational diabetes can lower the risk for large-for-gestational-age births without increasing the risk for serious maternal and neonatal complications.
1.
"We Caught It Early": Advantage or Disadvantage?
2.
Researchers discuss HER2-low and HER2-zero in breast cancer
3.
In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.
4.
Breast cancer: Why it's difficult to treat and what new approaches are on the horizon
5.
Standardized criteria for amino acid PET imaging could improve diagnosis and treatment of brain metastases
1.
From Diagnosis to Recovery: A Comprehensive Guide to Dealing with Cystic Teratoma
2.
Carboplatin Treatment: What You Need to Know About Side Effects and Efficacy
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
Immunotherapy Breakthroughs: Transforming Cancer Care Across All Oncology Fields
5.
Understanding Leiomyoma: Causes, Symptoms, and Treatment Options
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
3.
Navigating the Complexities of Ph Negative ALL - Part VI
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge